Yarin, 3 mg+0.03 mg 63 pcs

Contraception

contraception

Indications

contraception

Active ingredient

Drospirenone, Ethinylestradiol

Composition

film-coated tablets, each active tablet contains:

ethinyl estradiol 0.03 mg,

drospirenone 3.00 mg.

Contraindications

Thrombosis and thromboembolism, as well as conditions preceding thrombosis, currently or in history, cerebrovascular disorders; migraine with focal neurological symptoms currently or in history; diabetes mellitus with vascular complications; multiple or severe risk factors for venous or arterial thrombosis, including complicated lesions of the heart valve apparatus; atrial fibrillation; diseases of the cerebral vessels or coronary arteries; uncontrolled arterial hypertension; major surgery with prolonged immobilization; smoking over the age of 35; pancreatitis with severe hypertriglyceridemia currently or in history; liver failure and severe liver disease (until liver tests return to normal); liver tumors (benign or malignant) currently or in history; severe renal failure, acute renal failure; adrenal insufficiency; identified hormone-dependent malignant diseases (including genital organs or mammary glands) or suspicion of them; vaginal bleeding of unknown origin; pregnancy or suspicion of it; breastfeeding period; hypersensitivity to any of the components of the drug Yarina.

Use with caution. If any of the conditions/risk factors listed below currently exist, then the potential risk and expected benefit of using combined oral contraceptives should be carefully weighed in each individual case: risk factors for thrombosis and thromboembolism; diseases in which peripheral circulatory disorders may occur; hereditary angioedema; hypertriglyceridemia, liver disease; diseases that first appeared or worsened during pregnancy or against the background of previous use of sex hormones (for example, jaundice, cholestasis, cholelithiasis, otosclerosis with hearing impairment, porphyria, herpes of pregnant women, Sydenham’s chorea); postpartum period.

Side Effects

Menstrual irregularities such as irregular bleeding (spotting or bleeding) may occur, especially during the first months of use.

While taking combined oral contraceptives, women experienced other undesirable effects, the connection of which with taking the drugs has not been confirmed, but has not been refuted.

Detailed information is contained in the instructions for use.

Storage conditions

At room temperature no higher than 25 °C

Shelf life

3 years

Manufacturer

Bayer AG, Germany